This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Vatic announces manufacturing partnership with Abingdon Health

Vatic announces manufacturing partnership with Abingdon Health

04 Oct 2021

Abingdon Health plc (“Abingdon Health”), a leading international developer and manufacturer of high quality and effective rapid tests, and Vatic Health Limited (“Vatic”), a UK born health-tech company today announce that they have signed a manufacturing and supply agreement for the Vatic KnowNow™ rapid antigen test, used to detect active SARS CoV-2 in a saliva swab. The innovative science of Vatic’s KnowNow Test combined with one of the... Read more

Exscientia Announces Pricing of $304.7m Upsized IPO & $160m Concurrent Private Placements

Exscientia Announces Pricing of $304.7m Upsized IPO & $160m Concurrent Private Placements

30 Sep 2021

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS,... Read more

Physiomics PARTNER study recruits first patient

Physiomics PARTNER study recruits first patient

21 Sep 2021

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions is pleased to announce its PARTNER study has recruited its first patient.  The study, which received formal Health Research Authority (HRA) ethics approval in December 2020 and started recruiting just this month, has been commissioned to gather data for the further development of... Read more

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES

21 Sep 2021

DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES Former Novartis executive to lead emerging biotech with a novel precision approach to autoimmune disease, supported by recent senior appointments MiroBio is exclusively focused on checkpoint agonists produced by its unique discovery engine that comprehensively maps inhibitory checkpoint signaling pathways Clinical initiation... Read more

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

Exscientia in $70M collaboration for anti-virals against coronavirus & other pandemic potential viruses

08 Sep 2021

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches — Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More